UCB SA reported sharply higher revenue and profit for the first half-year, buoyed by favourable exchange rates and sharply higher sales for a trio of drugs for neurological and inflammatory diseases. Revenue was up by 21% to €1.92 billion while operating profit rose by 173% to €415 million.
